Home World News EMA Recommends a Change to the Terms of the Marketing Authorisation for... World News EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 388 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell... December 3, 2024 Promising Results Observed with Front-line Sintilimab Plus a Bevacizumab Biosimilar in... November 21, 2020 In memory of Dame Deborah James June 29, 2022 Mohs Surgery for Skin Cancer: What to Know and What to... March 28, 2023 Load more HOT NEWS New on NCI’s Websites for December 2022 2023 ASCO Annual Meeting Research Round Up: Advances in Treating Gynecologic... Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women... Will Ponsegromab Be a Game Changer for Cancer Cachexia?
